An angiotensin receptor blocker (ARB) valsartan-based regimen offered advantages over a calcium channel blocker (CCB) amlodipine-based regimen in preventing heart failure (HF) and diabetes in patients with hypertension, according to results of an analysis published in Hypertension.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Valsartan appears more effective than amlodipine in preventing HF, diabetes in patients with hypertension

Newsletter